Dual metabolic reprogramming by ONC201/TIC10 and 2-Deoxyglucose induces energy depletion and synergistic anti-cancer activity in glioblastoma
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Erschienen in
-
In: British Journal of Cancer (BJC) ; 122 (2020). - S. 1146-1157. - ISSN 0007-0920. - eISSN 1532-1827
- Schlagwort
-
Krebs
Glioblastom
Pharmakotherapie
- Ereignis
-
Veröffentlichung
- (wo)
-
Ulm
- (wer)
-
Universität Ulm
- (wann)
-
2020
- Urheber
-
Pruss, Maximilian
Dwucet, Annika
Tanriover, Mine
Hlavac, Michal
Kast, Richard Eric
Debatin, Klaus-Michael
Wirtz, Christian Rainer
Halatsch, Marc-Eric
Siegelin, Markus David
Westhoff, Mike-Andrew
Karpel-Massler, Georg
- DOI
-
10.18725/OPARU-49583
- URN
-
urn:nbn:de:bsz:289-oparu-49659-2
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
25.03.2025, 13:47 MEZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Pruss, Maximilian
- Dwucet, Annika
- Tanriover, Mine
- Hlavac, Michal
- Kast, Richard Eric
- Debatin, Klaus-Michael
- Wirtz, Christian Rainer
- Halatsch, Marc-Eric
- Siegelin, Markus David
- Westhoff, Mike-Andrew
- Karpel-Massler, Georg
- Universität Ulm
Entstanden
- 2020
Ähnliche Objekte (12)
Reprogramming of T cell‐derived small extracellular vesicles using IL2 surface engineering induces potent anti‐cancer effects through miRNA delivery
Myc depletion induces a pluripotent dormant state mimicking diapause
Liver X Receptor Agonist AZ876 Induces Beneficial Endogenous Cardiac Lipid Reprogramming and Protects Against Isoproterenol-Induced Cardiac Damage
Liver X Receptor Agonist AZ876 Induces Beneficial Endogenous Cardiac Lipid Reprogramming and Protects Against Isoproterenol-Induced Cardiac Damage
Games with synergistic preferences
Games with synergistic preferences
Targeted combination therapy : discovery and evaluation of synergistic anticancer effects of Anti-HER2-Duocarmycin antibody-drug conjugates combined with ATR inhibitors
Targeted Combination Therapy: Discovery and Evaluation of Synergistic Anticancer Effects of Anti-HER2-Duocarmycin Antibody-Drug Conjugates Combined with ATR Inhibitors
Ca2+ Depletion
Heterocyclic anticancer agents
New anticancer drugs
Imaging-assisted anticancer nanotherapy
Reprogramming of T cell‐derived small extracellular vesicles using IL2 surface engineering induces potent anti‐cancer effects through miRNA delivery
Myc depletion induces a pluripotent dormant state mimicking diapause
Liver X Receptor Agonist AZ876 Induces Beneficial Endogenous Cardiac Lipid Reprogramming and Protects Against Isoproterenol-Induced Cardiac Damage
Liver X Receptor Agonist AZ876 Induces Beneficial Endogenous Cardiac Lipid Reprogramming and Protects Against Isoproterenol-Induced Cardiac Damage
Games with synergistic preferences
Games with synergistic preferences
Targeted combination therapy : discovery and evaluation of synergistic anticancer effects of Anti-HER2-Duocarmycin antibody-drug conjugates combined with ATR inhibitors
Targeted Combination Therapy: Discovery and Evaluation of Synergistic Anticancer Effects of Anti-HER2-Duocarmycin Antibody-Drug Conjugates Combined with ATR Inhibitors
Ca2+ Depletion
Heterocyclic anticancer agents
New anticancer drugs
Imaging-assisted anticancer nanotherapy
Reprogramming of T cell‐derived small extracellular vesicles using IL2 surface engineering induces potent anti‐cancer effects through miRNA delivery
Myc depletion induces a pluripotent dormant state mimicking diapause
Liver X Receptor Agonist AZ876 Induces Beneficial Endogenous Cardiac Lipid Reprogramming and Protects Against Isoproterenol-Induced Cardiac Damage
Liver X Receptor Agonist AZ876 Induces Beneficial Endogenous Cardiac Lipid Reprogramming and Protects Against Isoproterenol-Induced Cardiac Damage
Games with synergistic preferences
Games with synergistic preferences
Targeted combination therapy : discovery and evaluation of synergistic anticancer effects of Anti-HER2-Duocarmycin antibody-drug conjugates combined with ATR inhibitors
Targeted Combination Therapy: Discovery and Evaluation of Synergistic Anticancer Effects of Anti-HER2-Duocarmycin Antibody-Drug Conjugates Combined with ATR Inhibitors
Ca2+ Depletion
Heterocyclic anticancer agents
New anticancer drugs